The validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
| Autor: | Søren Dinesen Østergaard, Ole Mors, Per Bech, Christoph U. Correll, Leslie Foldager |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Olanzapine Antipyretics Psychometrics Adolescent Antipsychotic agents medicine.medical_treatment Sensitivity and Specificity 03 medical and health sciences Young Adult 0302 clinical medicine Rating scale Outcome Assessment Health Care medicine Humans Pharmacology (medical) Ziprasidone Antipsychotic Biological Psychiatry Psychiatric Status Rating Scales Pharmacology Risperidone Psychopathology Positive and Negative Syndrome Scale business.industry Reproducibility of Results Middle Aged medicine.disease 030227 psychiatry Clinical trial Psychiatry and Mental health Neurology Schizophrenia Female Neurology (clinical) business 030217 neurology & neurosurgery Regular Articles Follow-Up Studies medicine.drug Clinical psychology |
| Zdroj: | Østergaard, S D, Foldager, L, Mors, O, Bech, P & Correll, C U 2018, ' The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study ', Schizophrenia Bulletin, vol. 44, no. 2, pp. 453-462 . https://doi.org/10.1093/schbul/sbx076 |
| ISSN: | 0924-977X |
| Popis: | It was recently demonstrated in acutely exacerbated schizophrenia that a 6-item version (PANSS-6: P1 = delusions, P2 = conceptual disorganization, P3 = hallucinations, N1 = blunted affect, N4 = social withdrawal, N6 = lack of spontaneity/flow of conversation) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) was scalable (all items provide unique information regarding syndrome severity) and able to separate the effect of antipsychotics from placebo. Here, we tested the validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) outpatient study. We examined (1) the scalability of PANSS-6 and PANSS-30; (2) the correlation between PANSS-6 and PANSS-30 total scores; (3) whether PANSS-6 could identify symptom remission (Andreasen criteria); and (4) the effect of the 5 antipsychotics studied in CATIE Phase-1, using PANSS-6 and PANSS-30 total scores as outcomes. We found that for the 577 subjects with complete PANSS ratings at baseline, month 1, 3, and 6, PANSS-6 was scalable, whereas PANSS-30 was not. In the 1432 subjects in the intention-to-treat (ITT) sample, PANSS-6 and PANSS-30 total scores were highly correlated (Spearman correlation coefficient = 0.86). Based on 5080 ITT ratings, PANSS-6 identified symptom remission with an accuracy of 0.99 (95% confidence interval = 0.99-0.99). In ITT analyses, PANSS-6 and PANSS-30 identified the same statistically significant differences in antipsychotic efficacy, ie, olanzapine was superior to risperidone (P-value PANSS-6 = 0.0003 and PANSS-30 = 0.0003) and ziprasidone (P-value PANSS-6 = 0.0018 and PANSS-30 = 0.0046). In conclusion, PANSS-6 is a brief schizophrenia rating scale that adequately measures severity, remission, and antipsychotic efficacy related to core positive and negative symptoms in clinical trials. Prospective studies of PANSS-6 in clinical practice are required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect